Document Classification

Section Type: METHODS

Text: Following evaluation for response and toxicity, eligible patients were randomized to receive either cisplatin 90 mg/m2 i. v. on day 1, etoposide 200 mg/m2 i. v. on day 3, cyclophosphamide 150 mg/m2/d orally on days 7 to 13, doxorubicin 35 mg/m2 i. v. on day 14 (CECA), or cisplatin 40 mg/m2 IV on days 1 to 5 and etoposide 200 mg/m2 i. v. on days 2 to 4 alternating at 3-week intervals with cyclophosphamide 150 mg/m2/d orally on days 1 to 7 and doxorubicin 35 mg/m2 IV on day 8 (HDP/VP/CA).